StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a report issued on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reduced their target price on shares of Minerva Neurosciences from $11.00 to $7.00 and set a neutral rating for the company in a research note on Thursday, May 2nd.
Check Out Our Latest Analysis on NERV
Minerva Neurosciences Trading Up 1.0 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.07. Equities research analysts forecast that Minerva Neurosciences will post -1.89 EPS for the current year.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Further Reading
- Five stocks we like better than Minerva Neurosciences
- Why Invest in 5G? How to Invest in 5G Stocks
- First Solar Stock: The Dawn of a New Rally in Share Prices
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Using the MarketBeat Dividend Yield Calculator
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.